Literature DB >> 6540826

Uptake and metabolism of cisplatin by rat kidney.

R Safirstein, P Miller, J B Guttenplan.   

Abstract

Cisplatin, an effective antineoplastic agent, is toxic to the kidney. Since the kidney's vulnerability to cisplatin may originate in its ability to accumulate and retain platinum to a greater degree than other organs, we studied the characteristics of the renal accumulation of platinum and investigated the nature of intracellular platinum. Cisplatin and ethylenediamminedichloroplatinum, nephrotoxic and antineoplastic liganded platinum compounds, were concentrated in rat renal cortical slices fivefold above medium concentration. Platinum uptake was energy- and temperature-dependent and could be inhibited by drugs which inhibit base transport. The organic anions para-aminohippurate and pyrazinoate did not reduce renal slice platinum uptake. Unbound platinum in the blood and urine was predominantly cisplatin but unbound platinum in kidney cytosol was not. This latter compound, in contrast to cisplatin, was not active as a mutagen. These studies suggest that the kidney accumulates platinum in part by transport or specific binding to the base transport system in the kidney and biotransforms it intracellularly. Unbound platinum in the cell is not cisplatin and may no longer be toxic.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6540826     DOI: 10.1038/ki.1984.86

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  39 in total

Review 1.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Effect of silymarin in the prevention of Cisplatin nephrotoxicity, a clinical trial study.

Authors:  Ali Momeni; Ali Hajigholami; Shohreh Geshnizjani; Soleiman Kheiri
Journal:  J Clin Diagn Res       Date:  2015-04-01

3.  An autoradiographic study of the intrarenal localisation and retention of cisplatin, iproplatin and paraplatin.

Authors:  C Ewen; A Perera; J H Hendry; C A McAuliffe; H Sharma; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  A model for ultrafilterable plasma platinum disposition in patients treated with cisplatin.

Authors:  P A Reece; I Stafford; J Russell; M Khan; P G Gill
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 5.  Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.

Authors:  V Pinzani; F Bressolle; I J Haug; M Galtier; J P Blayac; P Balmès
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Pitfalls of pharmacokinetic dosage guidelines in renal insufficiency.

Authors:  K Turnheim
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents.

Authors:  Shuang Cai; Yumei Xie; Neal M Davies; Mark S Cohen; M Laird Forrest
Journal:  J Pharm Sci       Date:  2010-06       Impact factor: 3.534

8.  Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II).

Authors:  M Dumas; C de Gislain; P d'Athis; V Chadoint-Noudeau; A Escousse; J Guerrin; N Autissier
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  Iron- and ascorbic acid-induced lipid peroxidation in renal microsomes isolated from rats treated with platinum compounds.

Authors:  J Hannemann; J Duwe; K Baumann
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Platinum complex-induced dysfunction of cultured renal proximal tubule cells. A comparative study of carboplatin and transplatin with cisplatin.

Authors:  F Courjault; D Leroy; L Coquery; H Toutain
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.